Mediomics

Executive Summary

Mediomics is a privately held biotechnology company based in St. Louis, Missouri, founded in 2004. The company specializes in developing and commercializing innovative assay kits and biosensors for research and diagnostic applications, leveraging its proprietary platform technologies for sensitive detection of a wide range of biomolecules. Despite being established for over two decades, Mediomics remains private with no disclosed funding rounds or revenue data, suggesting a niche market presence or bootstrapped operations. Its product portfolio likely caters to both academic research and clinical diagnostics, with potential applications in infectious disease, cancer biomarkers, and point-of-care testing. However, the lack of visible commercial partnerships or recent product launches indicates modest market penetration. The diagnostics industry is experiencing rapid growth driven by demand for rapid, sensitive, and decentralized testing, which could benefit Mediomics if it successfully scales its technology. Given its age and limited public traction, Mediomics may be at a inflection point where new product introductions or strategic alliances could unlock value.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Multiplex Assay Platform60% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Diagnostics Firm45% success
• Q1 2027FDA 510(k) Clearance for Key Diagnostic Test40% success